drug · small molecule
IDELALISIB
Marketedupdated 3mo agoby $GILD GILEAD SCIENCES, INC.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 10 investigational indications.
targets
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform
all catalysts(1)
Trials studying IDELALISIB
- phase4A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- phase3A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
- phase3A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- phase1ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
- phase3Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- phase3A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
- phase2A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
- phase1Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 11, 2030
~3.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Sep 2, 2033compositionUS 9469643
- Sep 2, 2033compositionUS 9469643
- Mar 5, 2033compositionUS 10730879
- Mar 5, 2033compositionUS 10730879
- Mar 5, 2033compositionUS 8865730
- Mar 5, 2033compositionUS 8865730
- Mar 11, 2030method-of-use (U-1914)US 94924493.6y
- Mar 11, 2030method-of-use (U-1914)US 94924493.6y
News(1)
- CLL-321 Trial Efficacy and Safety Results AnalysisPhase 3 results: pirtobrutinib boosts PFS, delays next treatment after prior BTK therapy, and shows low cardiac toxicity.onclive · 3mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that